COMMUNIQUÉS West-GlobeNewswire

Novo Nordisk A/S - share repurchase programme
09/02/2026
Bagsværd, Denmark, 9 February 2026 – On 4 February 2026, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 [...]
BeyondSpring to Participate at the 12th Annual Immuno-Oncology 360° Conference
09/02/2026
FLORHAM PARK, N.J., Feb. 09, 2026 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ: BYSI), a clinical-stage biopharmaceutical company developing first-in-class immune-modulating cancer therapies, today announced that the [...]
Memo Therapeutics AG Enters into a Collaboration and Option Agreement with CSL for Development of Recombinant Polyclonal IgG Technology
09/02/2026
PRESS RELEASE Strategic research collaboration to advance MTx’s recombinant polyclonal IgG technology Agreement includes R&D funding for exploratory work, technology access and, assuming exercise of the option by [...]
Kraig Biocraft Laboratories Poised for Explosive Spider Silk Production Growth
09/02/2026
2026 Production Plan Set for a Record 10 Metric Tons of Recombinant Spider Silk Cocoon Per Month ANN ARBOR, Mich., Feb. 09, 2026 (GLOBE NEWSWIRE) -- Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) ("the Company", "Kraig [...]
Ocugen Appoints Rita Johnson-Greene to Chief Financial Officer
09/02/2026
MALVERN, Pa., Feb. 09, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced the appointment of Rita [...]
Helsinn and ESTEVE expand their partnership extending the Distribution and Licence Agreement for AKYNZEO® and ALOXI® to Austria
09/02/2026
Helsinn and ESTEVE expand their partnership extending the Distribution and Licence Agreement for AKYNZEO ® and ALOXI ® to Austria Lugano, Switzerland – February 9th, 2026 – Helsinn Healthcare SA (“Helsinn”), a global [...]
MannKind Announces First Patient Enrolled in INHALE-1ST Pediatric Study Evaluating Afrezza® for Youth with Newly-Diagnosed Type 1 Diabetes (T1D)
09/02/2026
Study to assess safety, efficacy and treatment experience of starting inhaled insulin in youth aged 10 to <18 years recently diagnosed with T1D DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Feb. 09, 2026 (GLOBE [...]
Integra LifeSciences to Host Fourth Quarter and Full Year 2025 Financial Results Conference Call on February 26, 2026
09/02/2026
PRINCETON, N.J., Feb. 09, 2026 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ: IART), a leading global medical technology company, will release fourth quarter and full year 2025 financial results [...]
Novo Nordisk takes legal action against Hims & Hers to protect patients from unsafe, knock-off Wegovy® and Ozempic®
09/02/2026
Hims & Hers unlawfully mass markets unapproved versions of Novo Nordisk’s FDA-approved semaglutide medicines, deceiving patients and putting their health at risk Novo Nordisk takes decisive legal action to stop Hims [...]
SparingVision Successfully Completes PRODYGY Trial Patient Dosing with SPVN06, its Novel Neuroprotective Gene Therapy
09/02/2026
All patients dosed with SPVN06 in Phase I/II trial continue to demonstrate a favorable safety profile Initial data readout for this novel gene-agnostic therapy expected in 2027 Paris, February 9, 2026 – SparingVision (“ [...]
Oruka Therapeutics to Participate in Multiple Upcoming Conferences
09/02/2026
MENLO PARK, Calif., Feb. 09, 2026 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. (“Oruka”) (Nasdaq: ORKA), a clinical-stage biotechnology company developing novel biologics designed to set a new standard for the treatment [...]
Can-Fite: Receives Canadian Patent Allowance for Namodenoson as an Anti-Obesity Therapy
09/02/2026
Namodenoson’s oral safety profile and metabolic activity, position it as a promising candidate in the rapidly growing obesity treatment market Ramat Gan, Israel, Feb. 09, 2026 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd [...]
Zenas BioPharma Announces Late-Breaking Platform Presentation of Results from Phase 2 MoonStone Trial of Obexelimab in Relapsing Multiple Sclerosis at ACTRIMS Forum 2026
09/02/2026
- Obexelimab met the primary endpoint with a 95% relative reduction in new gadolinium (Gd)-enhancing T1 lesions compared with placebo over weeks 8 and 12 (p=0.0009) - - Separately announced 24-week data support the [...]
Avis aux médias : La journée Tout le monde en rouge attire l’attention sur la crise des maladies cardiaques chez les femmes au Canada
09/02/2026
OTTAWA, Ontario, 09 févr. 2026 (GLOBE NEWSWIRE) -- Le 13 février, la population canadienne célébrera la Journée Tout le monde en rouge , une campagne nationale de sensibilisation à la santé cardiaque des femmes. [...]
NervGen Pharma Appoints Adam Rogers as Chief Executive Officer to Continue Leading the Company’s Growth and Execution of Its Mission in Spinal Cord Injury
09/02/2026
VANCOUVER, British Columbia, Feb. 09, 2026 (GLOBE NEWSWIRE) -- NervGen Pharma Corp. (“NervGen” or the “Company") (TSXV: NGEN) (NASDAQ: NGEN), a clinical-stage biopharmaceutical company developing first-in-class [...]
Inotiv Reports First Quarter Financial Results for Fiscal 2026 and Provides Business Update
09/02/2026
– First quarter fiscal 2026 revenue increased 0.8% compared to prior year quarter to $120.9 million – First quarter fiscal 2026 operating loss increased 5.3% compared to prior year quarter to $16.3 million – Conference [...]
Bavarian Nordic – Completion of Share Buy-Back Program
09/02/2026
COPENHAGEN, Denmark, February 9, 2026 – Bavarian Nordic A/S (OMX: BAVA) announces that the share buy-back program, which was announced and initiated on January 7, 2026, has now been completed, reaching an aggregate [...]
Strong clinical data for Breye Therapeutics’ lead oral asset danegaptide presented at Angiogenesis, Exudation and Degeneration 2026 symposium
09/02/2026
Prof. Carl D. Regillo, MD, presented clinical data from the Phase 1b trial evaluating Breye Therapeutics’ lead candidate, danegaptide, in 24 patients with non-proliferative diabetic retinopathy (NPDR) with associated [...]
Memo Therapeutics AG Enters into a Collaboration and Option Agreement with CSL for Development of Recombinant Polyclonal IgG Technology
09/02/2026
PRESS RELEASE Strategic research collaboration to advance MTx’s recombinant polyclonal IgG technology Agreement includes R&D funding for exploratory work, technology access and, assuming exercise of the option by [...]

Pages